AIA Group Ltd Grows Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

AIA Group Ltd boosted its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 441.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 145,150 shares of the company's stock after buying an additional 118,357 shares during the period. AIA Group Ltd's holdings in Dr. Reddy's Laboratories were worth $2,292,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Robeco Institutional Asset Management B.V. boosted its position in shares of Dr. Reddy's Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after acquiring an additional 9,373,412 shares during the last quarter. Aikya Investment Management Ltd boosted its holdings in shares of Dr. Reddy's Laboratories by 416.1% in the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock valued at $88,590,000 after purchasing an additional 4,523,303 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Dr. Reddy's Laboratories by 397.2% during the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock valued at $77,311,000 after buying an additional 3,911,404 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Dr. Reddy's Laboratories by 462.1% during the 4th quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company's stock worth $44,444,000 after buying an additional 2,313,987 shares during the last quarter. Finally, Fisher Asset Management LLC raised its position in shares of Dr. Reddy's Laboratories by 402.5% in the 4th quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company's stock worth $38,981,000 after buying an additional 1,977,419 shares during the period. Hedge funds and other institutional investors own 3.85% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on RDY. StockNews.com downgraded Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th. Nomura cut Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th.

Dr. Reddy's Laboratories Trading Down 6.6 %

Shares of RDY stock traded down $0.87 during mid-day trading on Friday, reaching $12.37. The company's stock had a trading volume of 3,932,444 shares, compared to its average volume of 1,348,794. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $10.32 billion, a PE ratio of 19.69 and a beta of 0.51. The company's 50 day simple moving average is $13.33 and its 200-day simple moving average is $14.50. Dr. Reddy's Laboratories Limited has a 12-month low of $12.36 and a 12-month high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, research analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.